NetworkNewsBreaks – Silo Pharma Inc. (SILO) Comm

NetworkNewsBreaks – Silo Pharma Inc. (SILO) Committed to Psilocybin, Anti-Inflammatory Research

Silo Pharma (OTCQB: SILO) still believes in medicinal mushrooms despite the fact that they are currently outlawed by the U.S. government (though legal in Oregon and decriminalized in various cities and states). Recently, the company announced that the Translational Psychedelic Research (“TrPR”) Program at the University of California San Francisco (“UCSF”) had successfully dosed [with psilocybin] patients who have Parkinson’s disease. “Silo is exploring psilocybin’s anti-inflammatory possibilities in patients exhibiting signs of Parkinson’s,” reads a recent article. “Silo’s commitment to psilocybin and anti-inflammatory research includes: executing an option agreement with the University of Maryland, Baltimore, studying novel system-homing peptides that could potentially ‘home to the inflamed CNS [central nervous system] and can differentiate between diseased and healthy CNS tissue’…; collaborating with the UCSF to study the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinson’s, bipolar disorder and chronic back pain…; teaming up with the University of Maryland, Baltimore, for patented homing peptides to target rheumatoid arthritis…”

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer